Federated Hermes’s Checkmate Pharmaceuticals, Inc. Common Stock CMPI Stock Holding History

Federated Hermes’s Portfolio CMPI Stock Details CMPI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-30,636	Closed	-$98K	–	2352
2022 Q1	$98K	Buy	30,636 +544	+2%	+$1.56K	﹤0.01%	1661
2021 Q4	$87K	Buy	30,092 +10,092	+50%	+$37.6K	﹤0.01%	1724
2021 Q3	$79K	Buy	20,000 +3,831	+24%	+$19.7K	﹤0.01%	1803
2021 Q2	$96K	Sell	16,169 -10,781	-40%	-$76.2K	﹤0.01%	1801
2021 Q1	$327K	Hold	26,950	–	–	﹤0.01%	1629
2020 Q4	$393K	Sell	26,950 -23,050	-46%	-$294K	﹤0.01%	1580
2020 Q3	$575K	Buy	+50,000	New	+$641K	﹤0.01%	1440

Federated Hermes's CMPI Position: Q2 2022 in Review

Federated Hermes sold out of Checkmate Pharmaceuticals, Inc. Common Stock (CMPI) in Q2 2022, closing a stake of 30,636 shares — an estimated $98K sold.

Federated Hermes first reported a position in CMPI in Q3 2020 and held it in 7 quarters. The position peaked at $575K in Q3 2020. 0 funds tracked by Wall St. Rank hold CMPI as of Q2 2022.

Federated Hermes reported no remaining Checkmate Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Federated Hermes sold 30,636 Checkmate Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $98K.
Federated Hermes first reported a position in Checkmate Pharmaceuticals, Inc. Common Stock in Q3 2020 and held it in 7 quarters.
Federated Hermes's Checkmate Pharmaceuticals, Inc. Common Stock position peaked at $575K in Q3 2020.
0 funds tracked by Wall St. Rank held Checkmate Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Federated Hermes's 13F filing for Q2 2022, filed 15 Aug 2022.